Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.46 |
| ▸ | GOT1 | P17174 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 5/20 | 0.37 |
| ▸ | FNTB | P49356 | 5/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7483971 | 0.88 | FNTA (0.47) | CYP19A1FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL7482278 | 0.87 | FNTA (0.47) | CYP19A1FNTAFNTBPGGT1B | |
| SCHEMBL7483881 | 0.87 | FNTA (0.38) | CYP19A1FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL7748868 | 0.86 | FNTA (0.38) | CYP19A1FNTAFNTBPGGT1B | |
| SCHEMBL7482744 | 0.84 | FNTA (0.41) | CYP19A1FNTAFNTBPGGT1B | |
| SCHEMBL7584664 | 0.84 | FNTA (0.38) | CYP19A1FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL7750453 | 0.83 | FNTA (0.38) | CYP19A1FNTAFNTBPGGT1B | |
| SCHEMBL7480437 | 0.83 | CHRM2 (0.38) | CCR3CHRM2FNTAFNTBPGGT1B | |
| SCHEMBL7587917 | 0.81 | FNTA (0.41) | CYP19A1FNTAFNTBPGGT1B | |
| SCHEMBL7492267 | 0.81 | HCRTR1 (0.35) | CYP19A1FNTAFNTBMGLLKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002538121-A | — | — | 2002-11-12 | — | — | JP | claimed |
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | claimed |
| EP-1165084-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | MERCK & CO INC (US) | 2002-05-15 | — | — | EP | claimed |
| EP-1165084-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | Merck & Co., Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | claimed |
| WO-2000051614-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | claimed |
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1165084-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | MERCK & CO INC (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1165084-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | Merck & Co., Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000051614-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | GGT1, FNTA, GGPS1 | MAPK14 3698/4885CYP19A1 2104/4885GOT1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.